Management BIOS. These guys have great BIOs. They are serious and can definitely build a big company.
From CPAI's filed 8k's over the last year:
Garland A. Brown, Jr.
Garland A. Brown, Jr. is an attorney and co-founder of the Scottsdale, Arizona law firm, Weiss Brown. Mr. Brown has focused his practice on counseling emerging technology-based companies, entrepreneurs, and established businesses on a wide range of day-to-day legal and business issues including intellectual property matters and de facto general counsel services.
Mr. Brown has wide-ranging and exceptionally unique experience in the technology field that includes 12 years of senior-level experience in Redmond, Washington with Microsoft as both a lead software development engineer and as a Director in Antitrust Law Compliance. His time and experience at Microsoft, combined with his time in private practice as an attorney at the international law firm of Greenberg Traurig, has enabled him to draw on this vast experience to be a frequent speaker on issues related to early stage and emerging technology-based businesses.
Mark H. Conner
Mark H. Conner founded MARS Medical Systems, Inc. (“MARS”). Originally organized as Applied Software Techniques, Mr. Conner led the strategic direction of the company since its founding in 1984. As Chief Architect of all MARS products, Mr. Conner is a pioneer in the practice management industry by making NetPracticePM™ the first fully browser-based practice management solution in 1999.
Under the leadership of Mr. Conner, MARS, acquired by Noteworthy Medical Systems in 2008, again achieved an industry first in 2001 with the introduction of a series of powerful modules for NetPracticePM™. This suite of tools provided the first fully integrated and automated medical coding analysis, appointment reminders, eligibility verification, secure patient Web portal and mobile device charge capture system. Mr. Conner has successfully negotiated strategic partnerships with several major healthcare industry companies as the leader of Noteworthy's Sales and Service Partners (SSP) program.
On March 15, 2016, the Board of Directors (the “Board”) passed a resolution to appoint Terrance Owen as CFO.
Terrance Owen
Dr. Owen obtained a BSc (Honours) in Biology from the University of Victoria in 1968, a MSc in Biology from the University of New Brunswick in 1970, a PhD in Zoology from the University of British Columbia in 1974 and a MBA from Simon Fraser University in 1991.
From 2000 to 2013, Dr. Owen was the President, CEO & a Director of ALDA Pharmaceuticals Corp. (Since renamed Vanc Pharmaceuticals Inc.), serves as a Director and on the audit committees of three other public companies that are listed on the TSX Venture Exchange and was acting CFO for Sonoma Resources, Inc from 2013 to 2015.
From December, 1980 to April 2002, Dr. Owen was the President of Helix Biotech ULC, a laboratory providing DNA identity testing services for paternity, immigration and forensic cases. He was the President and a director of Helix BioPharma Corp. from July, 1995 to June, 1998.
Shareholder update
The Board is of the opinion that the appointment of the Executives will accelerate the completion of funding and acquisitions that are needed to establish the Company in the market for pain resolution.
The new team is believed to have the expertise and contacts that are needed to raise funds, complete the acquisition of clinics, implement best practices and standard operating procedures, achieve economies of scale, add ancillary services and create a national brand as planned by the Company since its inception.
In particular, the Executives are believed to have the experience and contacts required to present the Company to the financial markets in the US and secure the funding required to execute the Company’s business plan. As of the date of this Form 8-K, such discussions have been initiated by the Executives with a number of financing sources.
Further, the Executive’s knowledge of the medical services markets and experience with technology-based companies are expected to facilitate the identification of the most desirable acquisition, joint venture and licensing prospects.
